Aptose's TUS Achieves 100% Response Rate in AML Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2025
0mins
Source: Newsfilter
- Significant Efficacy: The TUS+VEN+AZA triplet therapy achieves a 100% complete response rate (CR/CRh) at 80mg and 120mg doses in newly diagnosed AML patients, demonstrating robust efficacy across diverse mutation backgrounds, which could transform AML treatment paradigms.
- Outstanding Safety: The therapy shows no dose-limiting toxicities (DLTs) across all evaluable TUS dose levels, with no drug-related deaths or severe adverse events reported, indicating excellent tolerability in clinical applications and enhancing patient confidence in treatment.
- High MRD Negativity Rate: Among treated patients, 78% achieved minimal residual disease (MRD) negativity as confirmed by central flow cytometry, indicating the therapy's effectiveness in eliminating residual disease, potentially offering better long-term survival prospects for patients.
- Clinical Trial Progress: The ongoing TUSCANY trial by Aptose shows that 9 out of 10 patients respond to the TUS triplet therapy, with preliminary results at the 160mg dose indicating early responses, further validating TUS's potential in AML treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
